Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly ... two more  consultants to its team for further ... a new proprietary cell permeable peptide platform technology ... cargo into the eye. Ms. ...
(Date:9/23/2014)... Mass. (PRWEB) September 23, 2014 Cambridge ... by Semantic Web technology, was named in the recent ... Gartner, Inc. , The report details key insights ... , According to Gartner analysts Michael Shanler and ... accelerate innovation activities, expose complex relationships with scientific stakeholders, ...
(Date:9/23/2014)... , September 23, 2014 ... System Transfer     Devices  (CSTD) for ... with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading CSTD ... Taiwan , China ... company continues to expand globally, and throughout the ...
(Date:9/23/2014)... 23, 2014 Marktech Optoelectronics has introduced ... violet emitters in the 280 nm wavelength range. This ... which range from 280nm to 405nm. These new devices ... as well as curing. Mark Campito, Marktech’s CEO states ... interest to manufacturers is that we offer it in ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Marktech Introduces its New Line of Deep UV Emitters 2
... N.J. , June 16 Soligenix, Inc. (OTC Bulletin ... today that it has entered into common stock purchase agreements with ... Soligenix,s North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this ... , ...
... ... has released two new boards based on the Altera Stratix® IV 820 devices. These ... and prototype their own products. , ... Richardson, Texas (PRWEB) June 16, 2010 -- IRIS Technologies Inc. ( www.iris-technologies.net ...
... ... METTLER TOLEDO has announced the release of iC ... chemical reactions by automatically developing a kinetic model that describes the ... reaction. The kinetic model can be used to simulate the effect ...
Cached Biology Technology:Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors 2Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors 3Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors 4IRIS Technologies Inc. Launches Two New Stratix IV FPGA-Based Boards 2IRIS Technologies Inc. Launches Two New Stratix IV FPGA-Based Boards 3A Faster Way to Understand and Optimize your Chemistry 2
(Date:9/23/2014)... of Health will award funds to support the next ... to improve ways of predicting drug safety and effectiveness. ... 3-D human tissue chips and combine them into an ... the human body. Led by the National Center for ... institutions at $17 million in 2014 with additional support ...
(Date:9/23/2014)... on insects to predict how climate change will affect ... for the first time that insects, fear of their ... they grow. , "In other words, it,s less about ... shape the growth, survival and distribution of insects." says ... Arctic postdoctoral researcher at Dartmouth. , The study ...
(Date:9/23/2014)... scientists who are fighting a cyberwar against cancer finds ... powerful ally. , "Recent research has found that cancer ... system, and we studied the interplay between cancer and ... the tables on cancer," said Rice University,s Eshel Ben-Jacob, ... Early Edition of the Proceedings of the National ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Insects' fear limits boost from climate change, Dartmouth study shows 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3
... A component of DNA that can both stimulate ... may hold hope for treating cancer and infection, Medical ... of CpG increase inflammation, part of the body,s way ... increasing expression of the enzyme indoleamine 2,3 dioxygenase, or ...
... A new study by researchers at Princeton University,s Woodrow ... that global climate change may lead to the retreat ... States, which could create unprecedented ecological restoration opportunities across ... time, global warming may enable other invasive plants to ...
... a surprising link between brain iron levels and ... from autism to major depression., Appearing in the ... this week, the study by Randy Blakely, ... a powerful in silico approach for discovering novel ...
Cached Biology News:DNA component can stimulate and suppress the immune response 2Climate change's impact on invasive plants in Western US may create restoration opportunities 2Climate change's impact on invasive plants in Western US may create restoration opportunities 3Climate change's impact on invasive plants in Western US may create restoration opportunities 4Researchers iron out new role for serotonin 2
... is the simplest, easiest-to-use system ever for ... handling capabilities,into their labs, or groups in ... applications on a separate instrument. Plate-handling is ... even when you have thousands of samples., ...
... Safe Deposit Service ECACC is able to accept ... cGMP for cryo-storage. The cell lines must be ... been produced in accordance with the requirements of ... freedom from mycoplasma, bacteria or fungi. What are ...
... provides cost effective cell culture services for ... antibodies. Quality at a reasonable price is ... research or commercial product, we strive toward ... as roller bottles, hollow fiber, and bioreactor ...
... Cell Bank Service The Human Genetic ... Epstein-Barr Virus (EBV) immortalisation of human peripheral ... of lymphoblastoid cell lines (LCLs). These cell ... and expandable source of genomic DNA and ...
Biology Products: